标题
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
作者
关键词
Follicular Lymphoma, Mantle Cell Lymphoma, Overall Response Rate, Nilotinib, Bendamustine
出版物
Journal of Hematology & Oncology
Volume 8, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-11-21
DOI
10.1186/s13045-015-0224-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
- (2015) A. Rothe et al. BLOOD
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
- (2015) Peter Hillmen et al. LANCET
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
- (2015) G S Choudhary et al. Cell Death & Disease
- ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
- (2014) S. Peirs et al. BLOOD
- Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
- (2014) V. Fresquet et al. BLOOD
- Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
- (2014) S. Suryani et al. CLINICAL CANCER RESEARCH
- Management of chronic lymphocytic leukemia
- (2014) P. Ghia et al. HAEMATOLOGICA
- SINE (selective inhibitor of nuclear export) – translational science in a new class of anti-cancer agents
- (2014) John Gerecitano Journal of Hematology & Oncology
- New antibody approaches to lymphoma therapy
- (2014) Tejas Suresh et al. Journal of Hematology & Oncology
- XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)
- (2014) Giovanni Gravina et al. Journal of Hematology & Oncology
- Nucleo-cytoplasmic transport as a therapeutic target of cancer
- (2014) Giovanni Luca Gravina et al. Journal of Hematology & Oncology
- Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
- (2014) Kaushal Parikh et al. Journal of Hematology & Oncology
- A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
- (2014) Caroline S Breton et al. Journal of Hematology & Oncology
- Homoharringtonine and omacetaxine for myeloid hematological malignancies
- (2014) Shuqing Lü et al. Journal of Hematology & Oncology
- Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199
- (2014) S L Khaw et al. LEUKEMIA
- A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells
- (2014) Uwe Reusch et al. mAbs
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
- (2013) C. J. Vandenberg et al. BLOOD
- ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets
- (2013) Meike Vogler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Ibrutinib and novel BTK inhibitors in clinical development
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
- (2013) Ethan Q Han et al. Journal of Hematology & Oncology
- MEK and the inhibitors: from bench to bedside
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- B-Raf and the inhibitors: from bench to bedside
- (2013) Tiangui Huang et al. Journal of Hematology & Oncology
- Targeting p53 by small molecules in hematological malignancies
- (2013) Manujendra N Saha et al. Journal of Hematology & Oncology
- The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
- (2013) Li Shi et al. Journal of Hematology & Oncology
- A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
- (2013) James D Mellor et al. Journal of Hematology & Oncology
- STAT inhibitors for cancer therapy
- (2013) Muhammad Furqan et al. Journal of Hematology & Oncology
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
- (2012) W. Haso et al. BLOOD
- Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumoursin vivo
- (2012) S Ackler et al. BRITISH JOURNAL OF PHARMACOLOGY
- Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: In vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737
- (2011) Kenji Ishitsuka et al. CANCER LETTERS
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
- (2010) Scott Ackler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs
- (2009) L. M. High et al. MOLECULAR PHARMACOLOGY
- ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
- (2008) Scott Ackler et al. MOLECULAR CANCER THERAPEUTICS
- In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
- (2008) K. D. Mason et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program
- (2007) Richard Lock et al. PEDIATRIC BLOOD & CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now